South China Morning Post · General

MindRank in Phase 3 trial with first AI-assisted new drug

· By Eunice Xu
Story summary

The company was aiming for approval in the second half of 2028, paving the way for a market launch in 2029

Read at South China Morning Post

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.

Your local edition.

Choose a timezone for story timestamps and date filters.